Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
[Current progress of research and use of microminipigs in drug development]
Kazuichi Nakamura1, Masayoshi Otake2
1Laboratory of Toxicology, School of Veterinary Medicine, Kitasato University.
Abstract:
The use of minipigs has been increasing in the areas of pharmacology researches and drug development. The microminipig developed by Fuji Micra Inc. (Shizuoka, Japan) inherits characteristics of other pig strains showing several similarities to humans in anatomy, physiology, omnivorousness and diurnal, but at the same time has several advantages over other pig strains because of its small size which allows easy keeping, handling and dosing, and saving of test substances. The microminipig weighs about 10 kg at the age of 6 months. Canine cages can be used to keep the animal. Swine leukocyte antigens (SLA) are defined in each individual animal which is useful for testing immunological reactions. As there are many similarities in metabolic enzymes and transporters to those in humans, the microminipig is a powerful animal model for toxicokinetic studies. Unfortunately as in other minipigs the microminipig is not appropriate for embryo-fetal development studies of antibody drugs due to its poor placental transfer, but can be used for other reproductive and developmental studies. Repeat dose toxicity, safety pharmacology, immunotoxicity and local tolerance studies should be also other arenas of this animal model.
Insights
The microminipig is a valuable animal model for drug development, offering advantages in handling and cost-effectiveness. Its similarities to humans make it suitable for toxicokinetic and safety pharmacology studies.
Area of Science:
- Pharmacology and Toxicology
- Animal Models in Drug Development
Background:
- Minipigs are increasingly utilized in pharmaceutical research and drug development.
- The microminipig, a specific strain, exhibits human-like anatomical and physiological traits, alongside practical advantages due to its small size.
Purpose of the Study:
- To highlight the utility of the microminipig as an animal model in various stages of drug development.
- To outline the specific applications and limitations of the microminipig in preclinical research.
Main Methods:
- Characterization of microminipig physiology, anatomy, and genetics (Swine Leukocyte Antigens - SLA).
- Evaluation of microminipig suitability for toxicokinetic, safety pharmacology, immunotoxicity, and reproductive studies.
Main Results:
- Microminipigs share significant similarities with humans in metabolic enzymes and transporters, crucial for toxicokinetic studies.
- Their small size facilitates easier handling, dosing, and reduces the cost of test substances.
- While not ideal for antibody drug embryo-fetal development studies due to poor placental transfer, they are suitable for other reproductive studies.
Conclusions:
- The microminipig is a powerful and cost-effective animal model for pharmacology and drug development, particularly for toxicokinetic and safety pharmacology.
- Its defined Swine Leukocyte Antigens (SLA) are beneficial for immunological assessments.
- Further research can explore its application in repeat dose toxicity, immunotoxicity, and local tolerance studies.
More Related Videos
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Electrical Current
In Vitro Drug Release Testing: Overview, Development and Validation
Sustainable Development
Current Density
Eddy Currents
Other major applications of eddy currents appear in metal detectors and the braking systems of trains and roller...

